LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aandelen Lijst・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Gesloten

SectorGezondheidszorg

12.48 3.48

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.48

Max

12.48

Belangrijke statistieken
By Trading Economics
Inkomsten	227M
Verkoop	139M
K/W Sectorgemiddelde	4.857 51.415
Winstmarge	163.843
Werknemers	1,796
EBITDA	1.3M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+59.87% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.2B
Vorige openingsprijs	9
Vorige sluitingsprijs	12.48

Nieuwssentiment

By Acuity

50%

155 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

14.24 / 14.78 Steun & Weerstand

Hutchison China MediTech Ltd ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 mei 2026, 22:47 UTC

Populaire aandelen

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 mei 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 mei 2026, 22:00 UTC

Belangrijke Marktbewegers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 mei 2026, 18:09 UTC

Belangrijke Marktbewegers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 mei 2026, 16:02 UTC

Winsten

Belangrijke Marktbewegers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 mei 2026, 14:55 UTC

Belangrijke Marktbewegers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 mei 2026, 14:43 UTC

Belangrijke Marktbewegers

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 mei 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:59 UTC

Acquisities, Fusies, Overnames

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 mei 2026, 21:50 UTC

Acquisities, Fusies, Overnames

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 mei 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 mei 2026, 21:16 UTC

Marktinformatie

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 20:19 UTC

Populaire aandelen

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 mei 2026, 19:41 UTC

Acquisities, Fusies, Overnames

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 mei 2026, 19:35 UTC

Marktinformatie

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 mei 2026, 19:33 UTC

Marktinformatie

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 mei 2026, 18:35 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 mei 2026, 17:28 UTC

Marktinformatie

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 mei 2026, 16:24 UTC

Acquisities, Fusies, Overnames

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

15 mei 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

15 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 mei 2026, 15:55 UTC

Marktinformatie

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 mei 2026, 15:20 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 mei 2026, 15:20 UTC

Marktinformatie

Silver Plunges on Inflation Worries -- Market Talk

15 mei 2026, 15:20 UTC

Winsten

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 mei 2026, 14:33 UTC

Marktinformatie

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer Vergelijking

Prijswijziging

Hutchison China MediTech Ltd ADR Prognose

Koersdoel

By TipRanks

59.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 20 USD 59.87%

Hoogste 20 USD

Laagste 20 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Hutchison China MediTech Ltd ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Hutchison China MediTech Ltd ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

14.24 / 14.78Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

155 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.